Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
MMW Fortschr Med ; 147 Suppl 3: 127-33, 2005 Oct 06.
Artigo em Alemão | MEDLINE | ID: mdl-16261949

RESUMO

UNLABELLED: BACKGROUND AND ISSSUES: Ginkgo biloba-extracts are often used in therapy of patients with dementia. In this study, benefit and structure of Ginkgo biloba-extract EGb 761 in treatment of patients with dementia was examined. PATIENTS AND METHODS: For the assessment of quality of life of care-taking relatives and patients as well as treatment costs were documented. The study was conducted as a non-randomised, two-armed cohort study with an open design for 683 slightly or moderately demented patients, aged between 65 and 80 years. Society's perspective was taken. Barthel-Index and MMST were also documented. Because of significant differences at inclusion of both cohorts, a matched-pairs-analysis and multiple regression analysis conducted. RESULTS: According to PLC a significant improvement in quality-of-life of care-taking relatives (p < 0.001) and patients (positive mood p = 0.018, negative mood p < 0.001) was only observed in the Ginkgo-cohort. Also Barthel-Index indicated an improvement in the Ginkgo-cohort (p < or = 0,001). MMST-scores increased significantly only in the Ginkgo-cohort (p < 0.001). Average total cost per patient amounted to 3.614,75 euro in the standard-cohort, whereas these costs per patient in the Ginkgo-cohort amounted to 3.031,78 euro (p = 0.067). Results were confirmed by matched-pairs-analysis. RESULTS: Ginkgo treatment has a valid place in caretaking structure of health services. Gingko attributes to a higher quality of life for both care-takers and patients, the progression of disease is slowed down and treatment costs are lower.


Assuntos
Atividades Cotidianas , Doença de Alzheimer/tratamento farmacológico , Cuidadores/psicologia , Fitoterapia , Extratos Vegetais/uso terapêutico , Qualidade de Vida/psicologia , Autocuidado , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/psicologia , Estudos de Coortes , Feminino , Alemanha , Ginkgo biloba , Pesquisa sobre Serviços de Saúde , Humanos , Masculino , Entrevista Psiquiátrica Padronizada , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Fitoterapia/psicologia , Estudos Prospectivos
3.
Fortschr Med Orig ; 120(4): 135-41, 2002 Dec 05.
Artigo em Alemão | MEDLINE | ID: mdl-12613271

RESUMO

The efficacy of antidemential agents proven in comprehensive studies and by clinical experience, now justifies an active and positive approach by the general physician to the diagnosis and treatment of patients with dementia. The proposals on how to implement diagnostic and therapeutic measures in the doctor's office comply both with medical quality criteria and the requirements for appropriateness of treatment and considerations of economy stipulated by German law. They therefore provide the basis for a modern diagnostic work-up and treatment strategy, which will also meet economical demands.


Assuntos
Doença de Alzheimer , Fenilcarbamatos , Idoso , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/tratamento farmacológico , Escalas de Graduação Psiquiátrica Breve , Carbamatos/uso terapêutico , Inibidores da Colinesterase/uso terapêutico , Di-Hidroergotoxina/uso terapêutico , Donepezila , Medicina de Família e Comunidade , Feminino , Seguimentos , Galantamina/uso terapêutico , Ginkgo biloba , Humanos , Indanos/uso terapêutico , Masculino , Memantina/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Nimodipina/uso terapêutico , Nootrópicos/uso terapêutico , Piperidinas/uso terapêutico , Piracetam/uso terapêutico , Escalas de Graduação Psiquiátrica , Fatores de Risco , Rivastigmina , Fatores de Tempo , Vasodilatadores/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...